View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Jan. 7 (HealthDay News) -- Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.
Jie Hong, M.D., from the Shanghai Jiao Tong University School of Medicine, and colleagues conducted a multicenter trial in which 304 patients with type 2 diabetes with coronary artery disease (mean age, 63.3 years) were randomized to receive glipizide (30 mg daily) or metformin (1.5 g daily) for three years. The composite end point was times to recurrent cardiovascular events, including death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke, or arterial revascularization.
The researchers found that both groups achieved a significant reduction in the level of glycated hemoglobin (7.1 percent in the glipizide group and 7.0 percent in the metformin group). Ninety-one participants developed 103 primary end points over a median follow-up of five years. The adjusted hazard ratio for the composites of cardiovascular events among the patients that received metformin versus glipizide was 0.54. There was no significant difference between the two groups for secondary end points and adverse events.
"Treatment with metformin for three years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide," the authors write.
The glipizide and metformin were provided by the Xinyi Pharmaceutical Co.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top